Oncaspar 750 U/ml powder for solution for injection/infusion.

DRUG2 trials

Sponsors

Pfizer Inc., Universitaetsklinikum Schleswig-Holstein

Conditions

Acute Lymphoblastic Leukemia (ALL)acute lymphoblastic leukemia in children and adolescents

Phase 2

B1931036 - A prospective, randomized, open-label phase 2 study to evaluate the superiority of Inotuzumab Ozogamicin monotherapy versus ALLR3 for induction treatment of childhood high risk first relapse B-cell precursor Acute Lymphoblastic Leukaemia

RecruitingCTIS2023-509810-13-00

Pfizer Inc.Acute Lymphoblastic Leukemia (ALL)

Start: 2023-05-13Target: 94Updated: 2025-10-27

Phase 3

AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

Active, not recruitingCTIS2023-509856-32-00

Universitaetsklinikum Schleswig-Holsteinacute lymphoblastic leukemia in children and adolescents

Start: 2018-07-15Target: 4250Updated: 2025-08-19